{"DataElement":{"publicId":"7231908","version":"1","preferredName":"Metastatic Diagnosis Thyroid Carcinoma Non-Neoplastic Finding Outcome","preferredDefinition":"The clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease of a malignant tumor that arises from the thyroid gland.","longName":"7115529v1.0:7231899v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7115529","version":"1","preferredName":"Metastatic Diagnosis Non-Neoplastic Finding","preferredDefinition":"Any diagnosis indicating the presence of metastatic disease._Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.","longName":"6841515v1.0:7115527v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"6841515","version":"1","preferredName":"Metastatic Diagnosis","preferredDefinition":"Any diagnosis indicating the presence of metastatic disease.","longName":"C162221","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Diagnosis","conceptCode":"C162221","definition":"Any diagnosis indicating the presence of metastatic disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFAFAB2-E712-5A45-E053-F662850A0775","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7115527","version":"1","preferredName":"Non-Neoplastic Finding","preferredDefinition":"Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.","longName":"C157510","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Neoplastic Finding","conceptCode":"C157510","definition":"Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AB6B918-95F3-6DF1-E053-F662850AE039","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"ONEDATA","dateModified":"2019-12-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"9AB6B918-9604-6DF1-E053-F662850AE039","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"KNABLEJ","dateModified":"2020-06-14","changeDescription":"6/14/20 jk added CPTAC ESCA Baseline CSI.  2/14/20 jk Released per CPTAC SME (Linda) review and approval.  12/27/19 jk created for CPTAC LIHC baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7231899","version":"1","preferredName":"Thyroid Carcinoma Non-Neoplastic Finding Outcome","preferredDefinition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and undifferentiated (anaplastic) carcinoma._Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease._The result of an action.","longName":"7231899v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Non-neoplastic finding absent","valueDescription":"Non-Neoplastic Finding Absent","ValueMeaning":{"publicId":"7114207","version":"1","preferredName":"Non-Neoplastic Finding Absent","longName":"7114207","preferredDefinition":"There is no non-neoplastic finding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Neoplastic Finding Absent","conceptCode":"C160178","definition":"There is no non-neoplastic finding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9AB144CE-D783-6FE4-E053-F662850A2278","latestVersionIndicator":"Yes","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-27","modifiedBy":"ONEDATA","dateModified":"2019-12-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2CB1894-2859-16B7-E053-F662850AE1AE","beginDate":"2019-12-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-08","modifiedBy":"ONEDATA","dateModified":"2020-04-08","deletedIndicator":"No"},{"value":"Nodular Hyperplasia","valueDescription":"Nodular Goiter","ValueMeaning":{"publicId":"7231901","version":"1","preferredName":"Nodular Goiter","longName":"7231901","preferredDefinition":"Goiter characterized by discrete tissue mass(es) that may or may not produce thyroid hormones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Goiter","conceptCode":"C131437","definition":"Goiter characterized by discrete tissue mass(es) that may or may not produce thyroid hormones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A219D6A4-05D2-3CD9-E053-F662850A2655","latestVersionIndicator":"Yes","beginDate":"2020-03-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-30","modifiedBy":"ONEDATA","dateModified":"2020-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A219D6A4-05EB-3CD9-E053-F662850A2655","beginDate":"2020-03-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-30","modifiedBy":"ONEDATA","dateModified":"2020-03-30","deletedIndicator":"No"},{"value":"Lymphocytic Thyroiditis","valueDescription":"Lymphocytic Thyroiditis","ValueMeaning":{"publicId":"3235654","version":"1","preferredName":"Lymphocytic Thyroiditis","longName":"3235654","preferredDefinition":"An inflammatory disorder that affects the thyroid gland.  It is characterized by the infiltration of the thyroid parenchyma by lymphocytes.  It includes Hashimoto thyroiditis and subacute lymphocytic thyroiditis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocytic Thyroiditis","conceptCode":"C38766","definition":"An inflammatory disorder that affects the thyroid gland.  It is characterized by the infiltration of the thyroid parenchyma by lymphocytes.  It includes Hashimoto thyroiditis and subacute lymphocytic thyroiditis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A36BDE24-5228-63F3-E040-BB89AD433B2F","latestVersionIndicator":"Yes","beginDate":"2011-05-16","endDate":null,"createdBy":"WHITES","dateCreated":"2011-05-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A219D6A4-05F5-3CD9-E053-F662850A2655","beginDate":"2020-03-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-30","modifiedBy":"ONEDATA","dateModified":"2020-03-30","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"5697874","version":"1","preferredName":"Other","longName":"5697874","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A253837-4DE2-5542-E053-F662850A338C","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-03-07","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A219D6A4-060A-3CD9-E053-F662850A2655","beginDate":"2019-12-24","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-30","modifiedBy":"ONEDATA","dateModified":"2020-03-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008526","version":"1","preferredName":"Anatomic Sites","preferredDefinition":"locations or structures in the human body.","longName":"ANAT_SITES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ED0F8B-4D91-332D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7231898","version":"1","preferredName":"Thyroid Gland Carcinoma Non-Neoplastic Finding Outcome","preferredDefinition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and undifferentiated (anaplastic) carcinoma.:Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.:The result of an action.","longName":"C4815:C157510:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Carcinoma","conceptCode":"C4815","definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Non-Neoplastic Finding","conceptCode":"C157510","definition":"Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A219D6A4-0592-3CD9-E053-F662850A2655","latestVersionIndicator":"Yes","beginDate":"2020-03-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-30","modifiedBy":"ONEDATA","dateModified":"2020-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A219D6A4-05A3-3CD9-E053-F662850A2655","latestVersionIndicator":"Yes","beginDate":"2020-03-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-30","modifiedBy":"KNABLEJ","dateModified":"2020-04-08","changeDescription":"4/8/20 jk upd PV \"none\" to \"Non-neoplastic finding absent\" per SME review; released VD.  4/1/20 jk per CPTAC use same \"None\" PV and CUI from Hepatocellular CRF.  Chg RS to \"Application\".  3/30/20 jk created for CPTAC THCA baseline CRF.  Incomplete pending \"None\" vs \"None Identified\" PV decision.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"10000439","version":"1","longName":"Thyroid","context":"OCCPR"},{"publicId":"6779571","version":"1","longName":"THCA Baseline","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Non-Neoplastic Findings","type":"Preferred Question Text","description":"Non-Neoplastic Findings","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A2183DBB-9547-0C29-E053-F662850A456E","latestVersionIndicator":"Yes","beginDate":"2020-03-30","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-03-30","modifiedBy":"KNABLEJ","dateModified":"2020-04-08","changeDescription":"4/8/20 jk Rleased per SME review and approval.  4/1/20 jk per CPTAC use same \"None\" PV and CUI from Hepatocellular CRF.  Chg RS to \"Application\".  3/30/20 jk created for CPTAC THCA baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}